Market Closed -
Nyse
04:00:02 2024-05-28 pm EDT
5-day change
1st Jan Change
83.47
USD
-1.21%
-2.72%
+25.10%
Sales 2024 *
5.31B
Sales 2025 *
5.78B
Capitalization
8.4B
Net income 2024 *
414M
Net income 2025 *
464M
EV / Sales 2024 *
2.04
x
Net Debt
2024
*
2.42B
Net Debt
2025
*
2.14B
EV / Sales 2025 *
1.83
x P/E ratio 2024 *
20.7
x
P/E ratio 2025 *
18.5
x
Employees
27,209
Yield 2024 *
0.72%
Yield 2025 *
0.72%
Free-Float
85.65%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Encompass Health Insider Sold Shares Worth $850,200, According to a Recent SEC Filing
May. 24
MT
Piedmont and Encompass Health Announces the Opening of Rehabilitation Hospital of Atlanta, A 40-Bed Inpatient Rehabilitation Hospital Located At 1968 Peachtree Road NW, Building 2 on the 6Th Floor
May. 23
CI
Encompass Health Poised for 'Solid Progress' on Development Front Due to Discharge Growth, Industry Demand, RBC Says
May. 22
MT
RBC Lifts Price Target on Encompass Health to $95 From $83, Cites 'Strong' Q1 Results, 2024 Guidance Boost; Outperform Kept
May. 22
MT
Transcript : Encompass Health Corporation Presents at Bank of America Health Care Conference 2024, May-14-2024 03:00 PM
May. 14
AREX Capital to mount board challenge against Enhabit, sources say
May. 09
RE
Encompass Health Announces the Opening of Encompass Health Rehabilitation Hospital of Kissimmee, A 50-Bed Inpatient Rehabilitation Hospital, Now Open in Florida
May. 07
CI
Encompass Health Insider Sold Shares Worth $1,220,739, According to a Recent SEC Filing
May. 07
MT
Declaration of Voting Results by Encompass Health Corporation
May. 06
CI
Transcript : Encompass Health Corporation - Shareholder/Analyst Call
May. 02
Encompass Health Declares Dividend on Common Stock, Payable on July 15, 2024
May. 02
CI
Encompass Health Insider Sold Shares Worth $3,745,152, According to a Recent SEC Filing
May. 01
MT
UBS Adjusts Encompass Health Price Target to $96 From $88, Maintains Buy Rating
Apr. 29
MT
Encompass Health Corporation Provides Earnings Guidance for 2024
Apr. 25
CI
Transcript : Encompass Health Corporation, Q1 2024 Earnings Call, Apr 25, 2024
Apr. 25
More news
Encompass Health Insider Sold Shares Worth $850,200, According to a Recent SEC Filing
May. 24
MT
RBC Lifts Price Target on Encompass Health to $95 From $83, Cites 'Strong' Q1 Results, 2024 Guidance Boost; Outperform Kept
May. 22
MT
Encompass Health Insider Sold Shares Worth $1,220,739, According to a Recent SEC Filing
May. 07
MT
Encompass Health Insider Sold Shares Worth $3,745,152, According to a Recent SEC Filing
May. 01
MT
UBS Adjusts Encompass Health Price Target to $96 From $88, Maintains Buy Rating
Apr. 29
MT
More recommendations
1 day -1.21%
1 week -2.72%
Current month +0.11%
1 month +1.21%
3 months +11.71%
6 months +29.23%
Current year +25.10%
More quotes
Managers
Title Age Since
Chief Executive Officer
62
92-12-31
Director of Finance/CFO
62
10-05-05
Chief Tech/Sci/R&D Officer
64
-
Members of the board
Title Age Since
Director/Board Member
69
13-01-24
Chairman
62
19-12-31
Director/Board Member
68
21-09-30
More insiders
Date
Price
Change
Volume
24-05-28
83.47
-1.21%
438,841
24-05-24
84.49
-0.07%
408,899
24-05-23
84.55
-0.94%
340,691
24-05-22
85.35
-0.52%
305,227
24-05-21
85.8
-0.36%
254,689
Delayed Quote
Nyse, May 28, 2024 at 04:00 pm EDT
More quotes
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides specialized rehabilitative treatment on an inpatient basis. It operates hospitals in 37 states and Puerto Rico, with concentrations in Florida and Texas. It operates 161 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. The Company provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals also treat patients with or recovering from the COVID-19 virus. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
More about the company
Last Close Price
83.47
USD
Average target price
96.5
USD
Spread / Average Target
+15.61%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1